Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Hospira 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Hospira 1Q

Specialty Injectable Pharmaceuticals up 13%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Hospira
 
1Q Revenues: $1.2 billion (+12%)

1Q Earnings: $75.6 million (+11%)

Comments: Growth in the quarter was driven by sales of Specialty Injectable Pharmaceuticals (SIP) in the U.S. (+17% to $665.5 million), as well as biosimilar sales in the Europe, Middle East and Africa (EMEA) segment. Global SIP sales were $808.5 million, up 13%. Sales growth offset the decline Precedex, which lost market exclusivity in 2H14.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics